Deal watch: Is deal-making becoming more difficult?

The article discusses the status of business negotiations in the drug industry based on the 2006-2010 data. It tackles the conflicting perceptions of business development executives (BDEs) from biotechnology companies and those from pharmaceutical firms on the status of business negotiations. It says that other than financial pressures, deal-making is affected by the pharmaceutical firms' failure to develop late-stage assets.